Mer­ck touts PhI­II Keytru­da da­ta in front­line en­dome­tri­al can­cer

In a boost to Mer­ck’s ef­forts of mov­ing block­buster drug Keytru­da to ear­li­er lines of treat­ment, Phase III da­ta in en­dome­tri­al can­cer pa­tients show sig­nif­i­cant …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER